Does the media refer more to CYTK or VERA?

In the previous week, Cytokinetics had 7 more articles in the media than Vera Therapeutics. MarketBeat recorded 13 mentions for Cytokinetics and 6 mentions for Vera Therapeutics. Cytokinetics' average media sentiment score of 0.84 beat Vera Therapeutics' score of 0.61 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KRYS or VERA?

In the previous week, Krystal Biotech had 4 more articles in the media than Vera Therapeutics. MarketBeat recorded 10 mentions for Krystal Biotech and 6 mentions for Vera Therapeutics. Krystal Biotech's average media sentiment score of 1.51 beat Vera Therapeutics' score of 0.61 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Vera Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ABVX or VERA?

Abivax is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Vera Therapeutics N/A N/A -$299.61M -$5.54 N/A

Is ABVX or VERA more profitable?

Vera Therapeutics' return on equity of -74.86% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Vera Therapeutics N/A -74.86% -60.18%

Does the media refer more to ABVX or VERA?

In the previous week, Abivax had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 8 mentions for Abivax and 6 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.61 beat Abivax's score of 0.35 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is QGEN or VERA more profitable?

Qiagen has a net margin of 19.16% compared to Vera Therapeutics' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Vera Therapeutics N/A -74.86% -60.18%

Does the media refer more to QGEN or VERA?

In the previous week, Vera Therapeutics had 4 more articles in the media than Qiagen. MarketBeat recorded 6 mentions for Vera Therapeutics and 2 mentions for Qiagen. Qiagen's average media sentiment score of 1.19 beat Vera Therapeutics' score of 0.61 indicating that Qiagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VERA or IBRX?

In the previous week, Vera Therapeutics had 3 more articles in the media than ImmunityBio. MarketBeat recorded 6 mentions for Vera Therapeutics and 3 mentions for ImmunityBio. Vera Therapeutics' average media sentiment score of 0.61 beat ImmunityBio's score of 0.51 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vera Therapeutics (VERA) Competitors

$34.26 +0.61 (+1.81%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$34.38 +0.12 (+0.35%)

As of 06/12/2026 07:23 PM Eastern

Compare

VERA vs. CYTK, KRYS, ABVX, QGEN, and IBRX

Should you buy Vera Therapeutics stock or one of its competitors? MarketBeat compares Vera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vera Therapeutics include Cytokinetics (CYTK), Krystal Biotech (KRYS), Abivax (ABVX), Qiagen (QGEN), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does Vera Therapeutics compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Cytokinetics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Vera Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Vera Therapeutics	N/A	-74.86%	-60.18%

Vera Therapeutics has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	99.15	-$784.96M	-$6.84	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

Cytokinetics currently has a consensus price target of $99.30, indicating a potential upside of 41.55%. Vera Therapeutics has a consensus price target of $78.00, indicating a potential upside of 127.67%. Given Vera Therapeutics' higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Cytokinetics had 7 more articles in the media than Vera Therapeutics. MarketBeat recorded 13 mentions for Cytokinetics and 6 mentions for Vera Therapeutics. Cytokinetics' average media sentiment score of 0.84 beat Vera Therapeutics' score of 0.61 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of Vera Therapeutics shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cytokinetics and Vera Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Vera Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

In the previous week, Krystal Biotech had 4 more articles in the media than Vera Therapeutics. MarketBeat recorded 10 mentions for Krystal Biotech and 6 mentions for Vera Therapeutics. Krystal Biotech's average media sentiment score of 1.51 beat Vera Therapeutics' score of 0.61 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Vera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Krystal Biotech has a net margin of 53.92% compared to Vera Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Vera Therapeutics	N/A	-74.86%	-60.18%

Krystal Biotech has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Krystal Biotech currently has a consensus price target of $324.11, indicating a potential upside of 1.93%. Vera Therapeutics has a consensus price target of $78.00, indicating a potential upside of 127.67%. Given Vera Therapeutics' higher probable upside, analysts clearly believe Vera Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Krystal Biotech has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	24.09	$204.83M	$7.48	42.51
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

Summary

Krystal Biotech beats Vera Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Vera Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

In the previous week, Abivax had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 8 mentions for Abivax and 6 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.61 beat Abivax's score of 0.35 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

Abivax has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Vera Therapeutics' return on equity of -74.86% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Vera Therapeutics	N/A	-74.86%	-60.18%

Abivax presently has a consensus target price of $130.08, indicating a potential upside of 34.72%. Vera Therapeutics has a consensus target price of $78.00, indicating a potential upside of 127.67%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

47.9% of Abivax shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Vera Therapeutics beats Abivax on 10 of the 13 factors compared between the two stocks.

How does Vera Therapeutics compare to Qiagen?

Qiagen (NYSE:QGEN) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Qiagen has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.65	$424.88M	$1.91	19.41
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

Qiagen has a net margin of 19.16% compared to Vera Therapeutics' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Vera Therapeutics	N/A	-74.86%	-60.18%

Qiagen presently has a consensus target price of $44.98, indicating a potential upside of 21.34%. Vera Therapeutics has a consensus target price of $78.00, indicating a potential upside of 127.67%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Qiagen has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

In the previous week, Vera Therapeutics had 4 more articles in the media than Qiagen. MarketBeat recorded 6 mentions for Vera Therapeutics and 2 mentions for Qiagen. Qiagen's average media sentiment score of 1.19 beat Vera Therapeutics' score of 0.61 indicating that Qiagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Qiagen beats Vera Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Vera Therapeutics compare to ImmunityBio?

Vera Therapeutics (NASDAQ:VERA) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by company insiders. Comparatively, 69.5% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Vera Therapeutics had 3 more articles in the media than ImmunityBio. MarketBeat recorded 6 mentions for Vera Therapeutics and 3 mentions for ImmunityBio. Vera Therapeutics' average media sentiment score of 0.61 beat ImmunityBio's score of 0.51 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vera Therapeutics currently has a consensus target price of $78.00, indicating a potential upside of 127.67%. ImmunityBio has a consensus target price of $14.20, indicating a potential upside of 100.00%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Vera Therapeutics is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Vera Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market.

Vera Therapeutics has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
ImmunityBio	$113.29M	65.64	-$351.40M	-$0.85	N/A

Vera Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
ImmunityBio	-606.15%	N/A	-59.53%

Summary

Vera Therapeutics beats ImmunityBio on 10 of the 15 factors compared between the two stocks.

Get Vera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERA vs. The Competition

Export

Metric	Vera Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.46B	$3.39B	$6.74B	$12.04B
Dividend Yield	N/A	2.25%	2.67%	5.61%
P/E Ratio	-6.18	20.00	24.02	24.44
Price / Sales	N/A	305.33	510.83	109.87
Price / Cash	N/A	124.89	44.01	55.64
Price / Book	4.04	8.32	10.65	6.78
Net Income	-$299.61M	$23.94M	$3.57B	$338.00M
7 Day Performance	6.10%	3.53%	0.83%	2.68%
1 Month Performance	-12.49%	-1.43%	0.09%	2.16%
1 Year Performance	50.66%	44.80%	25.18%	30.48%

Vera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERA Vera Therapeutics	2.8558 of 5 stars	$34.26 +1.8%	$78.00 +127.7%	+52.1%	$2.46B	N/A	N/A	40
CYTK Cytokinetics	3.3406 of 5 stars	$67.90 -5.0%	$99.30 +46.2%	+111.3%	$8.89B	$88.04M	N/A	250	Insider Trade
KRYS Krystal Biotech	2.6999 of 5 stars	$301.76 +0.3%	$324.11 +7.4%	+126.6%	$8.87B	$389.13M	40.34	210	Positive News Gap Up
ABVX Abivax	3.303 of 5 stars	$101.53 flat	$130.08 +28.1%	+1,275.4%	$8.09B	N/A	N/A	61
QGEN Qiagen	4.7616 of 5 stars	$36.28 -1.1%	$44.98 +24.0%	-25.7%	$7.56B	$2.09B	18.95	5,654	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERA) was last updated on 6/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vera Therapeutics (VERA) Competitors

VERA vs. CYTK, KRYS, ABVX, QGEN, and IBRX

How does Vera Therapeutics compare to Cytokinetics?

Summary

How does Vera Therapeutics compare to Krystal Biotech?

Summary

How does Vera Therapeutics compare to Abivax?

Summary

How does Vera Therapeutics compare to Qiagen?

Summary

How does Vera Therapeutics compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vera Therapeutics (VERA) Competitors

VERA vs. CYTK, KRYS, ABVX, QGEN, and IBRX

How does Vera Therapeutics compare to Cytokinetics?

Which has more volatility & risk, CYTK or VERA?

Is CYTK or VERA more profitable?

Which has better earnings & valuation, CYTK or VERA?

Do analysts prefer CYTK or VERA?

Does the media refer more to CYTK or VERA?

Do insiders & institutionals have more ownership in CYTK or VERA?

Summary

How does Vera Therapeutics compare to Krystal Biotech?

Does the media refer more to KRYS or VERA?

Do insiders & institutionals hold more shares of KRYS or VERA?

Is KRYS or VERA more profitable?

Which has more volatility and risk, KRYS or VERA?

Do analysts prefer KRYS or VERA?

Which has stronger valuation and earnings, KRYS or VERA?

Summary

How does Vera Therapeutics compare to Abivax?

Does the media refer more to ABVX or VERA?

Which has stronger valuation & earnings, ABVX or VERA?

Which has more risk & volatility, ABVX or VERA?

Is ABVX or VERA more profitable?

Do analysts prefer ABVX or VERA?

Do insiders & institutionals believe in ABVX or VERA?

Summary

How does Vera Therapeutics compare to Qiagen?

Which has stronger valuation & earnings, QGEN or VERA?

Is QGEN or VERA more profitable?

Do analysts prefer QGEN or VERA?

Do insiders & institutionals believe in QGEN or VERA?

Which has more risk & volatility, QGEN or VERA?

Does the media refer more to QGEN or VERA?

Summary

How does Vera Therapeutics compare to ImmunityBio?

Do institutionals & insiders have more ownership in VERA or IBRX?

Does the media prefer VERA or IBRX?

Do analysts recommend VERA or IBRX?

Which has more volatility & risk, VERA or IBRX?

Which has preferable earnings and valuation, VERA or IBRX?

Is VERA or IBRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools